Table 2 ClinicalTrials.Gov Registry: active COVID-19-related studies in sub-Saharan Africa^a.

	Country	Total no. of studies	No. of interventional studies (% of all studies)	No. of studies enrolling children aged <18 years (% of all studies)	No. of interventional studies enrolling children aged <18 years (% of studies enrolling children)
1	South Africa	8	6 (75.0)	0 (0.0)	N/A
2	Nigeria	4	3 (75.0)	0 (0.0)	N/A
3	Kenya	3	2 (66.7)	0 (0.0)	N/A
4	Zambia	3	1 (33.3)	0 (0.0)	N/A
5	Zimbabwe	3	1 (33.3)	0 (0.0)	N/A
6	Ghana	2	1 (50.0)	0 (0.0)	N/A
7	Malawi	2	0 (0.0)	0 (0.0)	N/A
8	Mozambique	2	0 (0.0)	0 (0.0)	N/A
9	Sudan	2	1 (50.0)	1 (50.0)^b	1 (100.0)
10	Tanzania	2	0 (0.0)	0 (0.0)	N/A
11	Botswana	1	0 (0.0)	0 (0.0)	N/A
12	Burkina Faso	1	0 (0.0)	0 (0.0)	N/A
13	Côte d’Ivoire	1	1 (100.0)	0 (0.0)	N/A
14	Democratic Republic of the Congo	1	0 (0.0)	1 (100.0)^c	0 (0.0)
15	Ethiopia	1	0 (0.0)	1 (100.0)^d	0 (0.0)
16	Gambia	1	0 (0.0)	0 (0.0)	N/A
17	Senegal	1	1 (100.0)	1 (100.0)^e	1 (100.0)
18	Uganda	1	1 (100.0)	0 (0.0)	N/A
	TOTAL sub-Saharan Africa	39^f	18 (46.2)	4 (10.3)	2 (50.0)
	United States of America	502	374 (74.5)	54 (10.7)	24 (44.4)

N/A not applicable.
^aRecruiting and not yet recruiting studies registered at ClinicalTrials.gov as of August 8, 2020.
^bSudanese participants aged 5–90 years. Testing oral Gum Arabic as dietary supplement and immune modulator for treatment.
^cCongolese participants aged 15–75 years. Promoting nutritional supplementation with local foods for COVID-19 patients.
^dEthiopian participants of all ages. Profiling immune responses to COVID-19.
^eParticipants aged ≥15 years. Testing safety and efficacy of hydroxychloroquine versus hydroxychloroquine and azithromycin for treatment.
^f23 unique studies across sub-Saharan Africa; there was no study exclusively targeting children aged <18 years.

Quick links

Search